EGFR

Epidermal growth factor receptor; ErbB-1; HER1

EGFR

Related Products

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.

EGFR Isoform Specific Products:

EGFR Isoform Comparison

EGFR Related Products (689)
Recombinant Proteins (77)
Antibodies (18)
EGFR Isoform Comparison

By Effects:	Inhibitors (615) Agonist (1) Degraders (10) Antagonist (1) Activators (5) Modulators (2) Chemicals (2) Inducers (4)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-155079

DZD1516		98.31%
DZD1516 is a potent and selective HER2 inhibitor (IC₅₀=0.56 nM) with good blood-brain permeability. DZD1516 exhibits antitumor activity in CNS and subcutaneous xenograft mouse models.

HY-P990049

Becotatug	Inhibitor	98.44%
Becotatug (JMT-101) is an IgG1 antibody targeting EGFR that can also be conjugated to Afatinib (HY-10261) and Osimertinib (HY-15772) as a synthetic ADC.

HY-130616

EGFR-IN-11	Inhibitor	99.30%
EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC₅₀ of 18 nM for triple mutant EGFR^{L858R/T790M/C797S}. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1.

HY-138627A

AST5902 trimesylate	Inhibitor	98.75%
AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an EGFR inhibitor.

HY-100214

EAI001	Inhibitor	99.88%
EAI001 is a potent, selective mutant epidermal growth factor receptor (EGFR) allosteric inhibitor with an IC₅₀ value of 24 nM for EGFR^L858R/T790M. EAI001 can be used for research of cancer.

HY-10261S

Afatinib-d₆	Inhibitor	≥99.0%
Afatinib-d₆ is deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor[1].

HY-P99684

Laprituximab	Inhibitor
Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289.

HY-108484

PP 3	Inhibitor	99.79%
PP 3 (Compound 3) is an EGFR tyrosine kinase inhibitor with an IC₅₀ of 2.7 μM.

HY-41404

Piperonylic acid		99.91%
Piperonylic acid is a natural molecule bearing a methylenedioxy function that closely mimics the structure of trans-cinnamic acid. Piperonylic Acid is a selective, mechanism-based inactivator of the trans-cinnamate 4-Hydroxylase. Piperonylic acid has anticancer, antioxidant and antibacterial activities.

HY-N6577

Astragaloside VI		99.95%
Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing.

HY-15729A

Rociletinib hydrobromide	Inhibitor	98.04%
Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.

HY-P99437

Anbenitamab	Inhibitor	99.22%
Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research.

HY-P99715

Losatuxizumab	Inhibitor
Losatuxizumab (ABT-806) is an anti-EGFR monoclonal antibody. Losatuxizumab binds to EGFR with EC₅₀s of 0.96 nM for EGFR wild-type, 0.09 nM for EGFR^C271A,C283A, 0.12 nM for EGFRvIII, 0.66 nM for EGFR1-501. Losatuxizumab can be used for research of EGFR-expressing cancers.

HY-116437

Selatinib	Inhibitor	99.83%
Selatinib is a reversible and orally active dual EGFR and ErbB2 inhibitor with IC₅₀s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects.

HY-112345

PD-089828	Inhibitor	98.07%
PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC₅₀s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC₅₀=0.18 µM). PD-089828 also inhibits MAPK with an IC₅₀ of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity.

HY-N2184

Furanodienone		99.90%
Furanodienone is one of the major bioactive constituents derived from Rhizoma Curcumae. Furanodienone induced apoptosis.

HY-P99866

Duligotuzumab
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody that specifically targets Her3 (ErbB3).

HY-132259

Depatuxizumab mafodotin
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used for cancer research.

HY-10531

ARRY-380 analog	Inhibitor	99.19%
ARRY-380 analog, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2.

HY-101426

RG14620	Inhibitor	98.09%
RG14620 is an EGFR inhibitor with an IC₅₀ of 3 μM.

Name
Email *

	Sorry, but the email address you supplied was invalid.

EGFR

EGFR

EGFR Isoform Specific Products:

EGFR Isoform Specific Products:

EGFR Related Products (689)

Recombinant Proteins (77)

Antibodies (18)

EGFR Isoform Comparison

EGFR Related Products (689):